AVE Science & Technology Co

AVE Science & Technology Co Rule of 40

The Rule of 40 of AVE Science & Technology Co (688067.SS) as of Oct 22, 2026 is 26.24 %. In the previous year, Rule of 40 was 13.11 % — a change of 100.07% (higher).

Rule of 40

26.24 %

YoY

100.07%

Last updated:

Rule of 40 of AVE Science & Technology Co is 2025 26.24 % . Rule of 40 of AVE Science & Technology Co was 2024 13.11 % . It decreases by 100.07% higher compared to the previous year.

The AVE Science & Technology Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
31.04 CNY
Jan 1, 2019
56.46 CNY
Jan 1, 2020
13.97 CNY
Jan 1, 2021
33.14 CNY
Jan 1, 2022
2.81 CNY
Jan 1, 2023
12.97 CNY
Jan 1, 2024
13.11 CNY
Jan 1, 2025
26.24 CNY
The AVE Science & Technology Co Rule of 40 history
YEARRule of 40YoY
26.24 %+100.07%
13.11 %+1.14%
12.97 %+361.24%
2.81 %-91.52%
33.14 %+137.32%
13.97 %-75.26%
56.46 %+81.88%
31.04 %-19.55%
38.59 %-14.94%
45.36 %+40.59%
32.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

Rule of 40 of AVE Science & Technology Co is 26.24 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co